Literature DB >> 30886361

Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus.

Atsuhiro Yasuhara1, Seiya Yamayoshi2, Maki Kiso1, Yuko Sakai-Tagawa1, Michiko Koga3, Eisuke Adachi4, Tadashi Kikuchi5, I-Hsuan Wang1, Shinya Yamada1, Yoshihiro Kawaoka6,7,8,9.   

Abstract

Influenza viruses possess two surface glycoproteins, haemagglutinin and neuraminidase (NA). Although haemagglutinin plays a major role as a protective antigen, immunity to NA also contributes to protection. The NA protein consists of a stalk and a head portion, the latter of which possesses enzymatic NA (or sialidase) activity. Like haemagglutinin, NA is under immune pressure, which leads to amino acid alterations and antigenic drift. Amino acid changes accumulate around the enzymatic active site, which is located at the top of the NA head. However, amino acid alterations also accumulate at the lateral surface of the NA head. The reason for this accumulation remains unknown. Here, we isolated seven anti-NA monoclonal antibodies (mAbs) from individuals infected with A(H1N1)pdm09 virus. We found that amino acid mutations on the lateral surface of the NA head abolished the binding of all of these mAbs. All seven mAbs activated Fcγ receptor (FcγR)-mediated signalling pathways in effector cells and five mAbs possessed NA inhibition activity, but the other two did not; however, all seven protected mice from lethal challenge infection through their NA inhibition activity and/or FcγR-mediated antiviral activity. Serological analysis of individuals infected with A(H1N1)pdm09 virus revealed that some possessed or acquired the anti-NA-lateral-surface antibodies following infection. We also found antigenic drift on the lateral surface of the NA head of isolates from 2009 and 2015. Our results demonstrate that anti-lateral-surface mAbs without NA inhibition activity can provide protection by activating FcγR-mediated antiviral activity and can drive antigenic drift at the lateral surface of the NA head. These findings have implications for NA antigenic characterization in that they demonstrate that traditional NA inhibition assays are inadequate to fully characterize NA antigenicity.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30886361     DOI: 10.1038/s41564-019-0401-1

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   17.745


  23 in total

1.  Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.

Authors:  Ryuta Uraki; Maki Kiso; Shun Iida; Masaki Imai; Emi Takashita; Makoto Kuroda; Peter J Halfmann; Samantha Loeber; Tadashi Maemura; Seiya Yamayoshi; Seiichiro Fujisaki; Zhongde Wang; Mutsumi Ito; Michiko Ujie; Kiyoko Iwatsuki-Horimoto; Yuri Furusawa; Ryan Wright; Zhenlu Chong; Seiya Ozono; Atsuhiro Yasuhara; Hiroshi Ueki; Yuko Sakai-Tagawa; Rong Li; Yanan Liu; Deanna Larson; Michiko Koga; Takeya Tsutsumi; Eisuke Adachi; Makoto Saito; Shinya Yamamoto; Masao Hagihara; Keiko Mitamura; Tetsuro Sato; Masayuki Hojo; Shin-Ichiro Hattori; Kenji Maeda; Riccardo Valdez; Moe Okuda; Jurika Murakami; Calvin Duong; Sucheta Godbole; Daniel C Douek; Ken Maeda; Shinji Watanabe; Aubree Gordon; Norio Ohmagari; Hiroshi Yotsuyanagi; Michael S Diamond; Hideki Hasegawa; Hiroaki Mitsuya; Tadaki Suzuki; Yoshihiro Kawaoka
Journal:  Nature       Date:  2022-05-16       Impact factor: 69.504

2.  Antigenic comparison of the neuraminidases from recent influenza A vaccine viruses and 2019-2020 circulating strains.

Authors:  Jin Gao; Xing Li; Laura Klenow; Tahir Malik; Hongquan Wan; Zhiping Ye; Robert Daniels
Journal:  NPJ Vaccines       Date:  2022-07-14       Impact factor: 9.399

3.  Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination.

Authors:  Xuemin Chen; He-Ying Sun; Chun Yi Lee; Christina A Rostad; Jessica Trost; Rodrigo B Abreu; Michael A Carlock; Jason R Wilson; Shane Gansebom; Ted M Ross; David A Steinhauer; Evan J Anderson; Larry J Anderson
Journal:  Virology       Date:  2022-02-24       Impact factor: 3.513

4.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

5.  Analysis of the Evolution of Pandemic Influenza A(H1N1) Virus Neuraminidase Reveals Entanglement of Different Phenotypic Characteristics.

Authors:  Meiling Dai; Wenjuan Du; Carles Martínez-Romero; Tim Leenders; Tom Wennekes; Guus F Rimmelzwaan; Frank J M van Kuppeveld; Ron A M Fouchier; Adolfo Garcia-Sastre; Erik de Vries; Cornelis A M de Haan
Journal:  mBio       Date:  2021-05-11       Impact factor: 7.867

6.  Neuraminidase antigenic drift of H3N2 clade 3c.2a viruses alters virus replication, enzymatic activity and inhibitory antibody binding.

Authors:  Harrison Powell; Andrew Pekosz
Journal:  PLoS Pathog       Date:  2020-06-29       Impact factor: 6.823

7.  The Phylodynamics of Seasonal Influenza A/H1N1pdm Virus in China Between 2009 and 2019.

Authors:  Yingying Ma; Kai Liu; Yong Yin; Jianru Qin; Yan-Heng Zhou; Juan Yang; Shenwei Li; Leo L M Poon; Chiyu Zhang
Journal:  Front Microbiol       Date:  2020-04-28       Impact factor: 5.640

8.  Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.

Authors:  E R Job; T Ysenbaert; A Smet; A Van Hecke; L Meuris; H Kleanthous; X Saelens; T U Vogel
Journal:  mBio       Date:  2019-10-22       Impact factor: 7.867

Review 9.  Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections.

Authors:  Shamus P Keeler; Julie M Fox
Journal:  Viruses       Date:  2021-05-31       Impact factor: 5.048

10.  Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.

Authors:  Iuliia M Gilchuk; Sandhya Bangaru; Pavlo Gilchuk; Ryan P Irving; Nurgun Kose; Robin G Bombardi; Natalie J Thornburg; C Buddy Creech; Kathryn M Edwards; Sheng Li; Hannah L Turner; Wenli Yu; Xueyong Zhu; Ian A Wilson; Andrew B Ward; James E Crowe
Journal:  Cell Host Microbe       Date:  2019-11-19       Impact factor: 31.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.